ArticleNeuro-oncology2022
A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act.
Article in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Pooled it
- Demographic reporting across a decade of neuroimaging: a systematic review.Brain imaging and behavior · 2022Pooled it
- The Impact of Sociodemographic Disparities on Health-Related Quality of Life for Adults with Gliomas.Cancers · 2026Review
- Addressing the balance between fairness and performance in glioma grade prediction using bias mitigation techniques.Scientific reports · 2026Article
- Evaluating Minority Participation in Radiation Oncology Clinical Trials and the Impact of COVID-19 on Enrollment in a Large Integrated Academic Satellite Network.JCO oncology advances · 2026Article
- Gaps in Diagnosis, Treatment, and Outcomes Among Patients with Brain Tumors in the United States: A State-of-the-Art Review.Cancers · 2025Review
- Socioeconomic Factors Associate With Access but not Survival in Neurosurgical Brain Tumor Patients.World neurosurgery · 2025Article
- Epileptogenesis in meningioma: Theories, putative biomarkers, and postoperative risk.Epilepsia · 2025Review
- Health disparities in neurology.Nature reviews. Neurology · 2025Review
- From Dialogue to Action: Community Recommendations for Inclusive Research Participation Among Underrepresented Populations.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- Predicting therapeutic clinical trial enrollment for adult patients with low- and high-grade glioma using supervised machine learning.Science advances · 2025Article
- Racial, ethnic, and socioeconomic disparities in clinical trial reporting for metastatic spine tumors: An exploration of North American studies.Neurosurgical review · 2025Review
- Analysis of epidemiology and nomogram construction for prediction and clinical decision-making in gliomas.Frontiers in immunology · 2025Article
- The role of social, economic, and medical marginalization in cancer clinical trial participation inequities: A systematic review.Journal of clinical and translational science · 2025Review
- Enhancing neuro-oncology care through equity-driven applications of artificial intelligence.Neuro-oncology · 2024Review
- Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.Neuro-oncology · 2024Article
- Article
- Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual.Frontiers in health services · 2024Article
- Health Disparities, Clinical Trials, and the Digital Divide.Mayo Clinic proceedings · 2023Review
- Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.Nature medicine · 2023Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundThe NIH Revitalization Act, implemented 29 years ago, set to improve the representation of women and minorities in clinical trials. In this study, we investigate progress made in all phase therapeutic clinical trials for neuroepithelial CNS tumors stratified by demographic-specific age-adjusted disease incidence and mortality. Additionally, we identify workforce characteristics associated with clinical trials meeting established accrual benchmarks.
methodsRegistry study of published clinical trials for World Health Organization defined neuroepithelial CNS tumors between January 2000 and December 2019. Study participants were obtained from PubMed and ClinicalTrials.gov. Population-based data originated from the CBTRUS for incidence analyses. SEER-18 Incidence-Based Mortality data was used for mortality analysis. Descriptive statistics, Fisher exact, and χ 2 tests were used for data analysis.
resultsAmong 662 published clinical trials representing 49 907 participants, 62.5% of participants were men and 37.5% women (P < .0001) representing a mortality specific over-accrual for men (P = .001). Whites, Asians, Blacks, and Hispanics represented 91.7%, 1.5%, 2.6%, and 1.7% of trial participants. Compared with mortality, Blacks (47% of expected mortality, P = .008), Hispanics (17% of expected mortality, P < .001) and Asians (33% of expected mortality, P < .001) were underrepresented compared with Whites (114% of expected mortality, P < .001). Clinical trials meeting accrual benchmarks for race included minority authorship.
conclusionsFollowing the Revitalization Act, minorities and women remain underrepresented in therapeutic clinical trials for neuroepithelial tumors, relative to disease incidence and mortality. Study accrual has improved with time. This study provides a framework for clinical trial accrual efforts and offers guidance regarding workforce considerations associated with enrollment of underserved patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.